$3.52
+0.02 (+0.57%)
Open$3.50
Previous Close$3.50
Day High$3.58
Day Low$3.36
52W High$21.00
52W Low$1.33
Volume—
Avg Volume3.25M
Market Cap11.45M
P/E Ratio—
EPS$-5.99
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+460.2% upside
Current
$3.52
$3.52
Target
$19.72
$19.72
$18.07
$19.72 avg
$32.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 850.6K | 846.2K | 822.4K |
| Net Income | -189,460 | -228,334 | -201,883 |
| Profit Margin | -22.3% | -27.0% | -24.6% |
| EBITDA | -320,116 | -324,230 | -315,475 |
| Free Cash Flow | -189,627 | -182,540 | -129,892 |
| Rev Growth | +3.9% | -4.1% | +22.7% |
| Debt/Equity | 0.68 | 0.61 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |